menu
    • menu

    Company profile for Nippon Shinyaku

    NEW Drugs in Dev: 6
    FAMAR CDMO- From early development to commercial manufacturing.

    Virtual Booth

    Contact Supplier

    Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    AbbVie Contract Manufacturing partners globally to develop, scale, and manufacture pharmaceutical products successfully.

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    EXCIPIENTS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Nippon Shinyaku aims to be trusted and respected by society as a company that plays a meaningful role in the healthcare sector. Our mission is to help people lead healthier and happier lives. Through creating unique medicines that will bring hope to patients and families struggling with illness, we aim to be an organization trusted by the community.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Nippon Shinyakujapan Flag
    Country
    Country
    Japan
    Address
    Address
    14, Nishinosho-Monguchi-cho, Kisshoin, Minami-ku, Kyoto 601-8550
    Telephone
    Telephone
    +81-75-321-1111
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.nippon-shinyaku.co.jp/english/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    PEGS Boston Summit

    PEGS Boston Summit

    Not Confirmed

    envelop Contact Supplier

    PEGS Boston Summit

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Capricor Sues Nippon Shinyaku Over Duchenne Drug Price Flaw
    Capricor Sues Nippon Shinyaku Over Duchenne Drug Price Flaw

    08 May 2026

    // ENDPOINTS

    https://endpoints.news/capricor-sues-nippon-shinyaku-over-duchenne-drug-pricing-flaw-and-launch-prep/

    ENDPOINTS
    08 May 2026
    Share Share
    MDA 2026 Spotlights Brogidirsen's 4.5-Year DMD Data
    MDA 2026 Spotlights Brogidirsen's 4.5-Year DMD Data

    09 Mar 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/brogidirsen-ns-089ncnp-02-4-5-year-clinical-trial-data-for-the-treatment-of-duchenne-muscular-dystrophy-presented-at-2026-mda-clinical--scientific-conference-302708276.html

    PR NEWSWIRE
    09 Mar 2026
    Share Share
    Brogidirsen 3.5Y Trial Shows Results in Duchenne MD at WMS 2025
    Brogidirsen 3.5Y Trial Shows Results in Duchenne MD at WMS 2025

    14 Oct 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/brogidirsen-ns-089ncnp-02-3-5-year-clinical-trial-data-for-the-treatment-of-duchenne-muscular-dystrophy-presented-at-2025-world-muscle-society-congress-302580951.html

    PR NEWSWIRE
    14 Oct 2025
    Share Share
    Buloxibutid Granted Orphan Drug Status In Japan For IPF
    Buloxibutid Granted Orphan Drug Status In Japan For IPF

    30 Sep 2025

    // ACCESSWIRE

    https://www.accessnewswire.com/newsroom/en/biotechnology/buloxibutid-receives-orphan-drug-designation-in-japan-for-the-treatment-of-idiopathic-1079860

    ACCESSWIRE
    30 Sep 2025
    Share Share
    FDA Fast Tracks NS-229 for Eosinophilic Granulomatosis Treatment
    FDA Fast Tracks NS-229 for Eosinophilic Granulomatosis Treatment

    09 Sep 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/fda-grants-fast-track-designation-to-ns-229-for-the-treatment-of-eosinophilic-granulomatosis-with-polyangiitis-302550236.html

    PR NEWSWIRE
    09 Sep 2025
    Share Share
    NS Pharma, Boston Children's Hospital Ally for Rare Diseases
    NS Pharma, Boston Children's Hospital Ally for Rare Diseases

    01 Jul 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/ns-pharma-announces-strategic-alliance-with-boston-childrens-hospital-to-develop-new-therapies-for-rare-diseases-302494701.html

    PR NEWSWIRE
    01 Jul 2025
    Share Share

    Excipients

    Click here to find the perfect excipient manufacturers by their capabilities

    Inspections and registrations

    Upload your audits for free, ask us

    ABOUT THIS PAGE

    Contact Nippon Shinyaku and get a quotation

    Nippon Shinyaku is a supplier offers 2 products (APIs, Excipients or Intermediates).

    Find Fluoromethane Sulfoanilide Hydrochloride bulk offered by Nippon Shinyaku

    Find NS-065/NCNP-01 bulk offered by Nippon Shinyaku

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search